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Abstract
Patient reported outcomes including quality of life (QoL) assessments are increasingly being
included as either primary or secondary outcomes in randomized controlled trials. While making
the outcomes more relevant for patients it entails a challenge in cases where death or a similar
event makes the outcome of interest undefined. A pragmatic - and much used - solution is to
assign diseased patient with the lowest possible QoL score. This makes medical sense, but creates
a statistical problem since traditional tests such as t-tests or Wilcox tests potentially looses large
amounts of statistical power. In this paper we propose a novel test that can keep the medical
relevant composite outcome, but preserve full statistical power. The test is also applicable in
other situations where a specific value (say 0 days alive outside hospitals) encodes a special
meaning. The test is implemented in an R package which is available for download.
Keywords: quality of life, RCT, tests.
1 Introduction
In medical intervention research including in particular randomized controlled trials (RCTs) there is
a trend towards increased use of patient reported outcomes; Quality of Life (QoL) scores are one of
the most prominent of these. Established statistical practice is to compare these between treatment
groups using non-parametric tests such as Wilcox since distributions are rarely normal. When all
patients are alive and able and willing to provide QoL scores at the scheduled measurement time
this procedure works very well. Not all clinical settings, however, will have all participants alive at
time of scheduled assessment of QoL. This is particular true in trials within intensive care where
mortality approximating 30% are not uncommon and which is the setting that have motivated
this work. A pragmatic solution which is gaining popularity is to simply give the diseased patient
the lowest possible score and then use a Wilcoxon test or similar to compare groups. This paper
will demonstrate that this approach can lead to dramatic loss of statistical power. The paper will
also presents an alternative and novel statistical test which avoids the power loss. The novel test
procedure is implemented in R and made publicly available.
The key-insight in the proposed test is to incorporate that the outcome is actually a two-dimensional
outcome of a very special type and that the constructed combined outcome follows a continuous-
singular mixture distribution. This unusual distribution is why one cannot resort to non-parametric
Wilcoxon (Mann-Whitney) tests since the singular component of the distribution of the combined
outcome will get reduced to simple ties. It is noted that the handling of ties in standard statistical
software varies and is opaque. However, the handling of ties is not the main reason why Wilcox suffers
power loss. The main reason is that the null-hypothesis in these Wilcoxon type tests (stochastic
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domination) does not handle the empirical fact that treatments might influence mortality and QoL
differently.
As an alternative we propose to model the binary component (i.e., survival) and the continuous
part (i.e., actual QoL) separately but to conduct a single test for no treatment effect on either. We
can thus provide a single p-value for the hypothesis of no treatment effect on the extended QoL
where death is given the lowest possible score. To accommodate potential non-normality of the
recorded QoL scores we include both parametric and a semi-parametric tests where the latter is as
widely applicable as the Wilcox test. Simulations indicate that the semi-parametric is preferred
as is greatly extends applicability of the test procedure at a very low price in terms of reduced
power. Both test procedures will provide effect estimates of mean differences between treatment
groups based on the combined outcome along with corresponding confidence intervals. This is also
an added benefit compared to the Wilcox-type based testing approach.
It should be noted that while we in this paper exemplifies the procedure using QoL tests and
mortality the method is applicable in any setting where a single value of a combined outcome has
a special interpretation compared to an otherwise continuous scale. As an example, again from
intensive care research, consider the outcome “days alive and out of hospital within 90 days from
randomization”. Here in-hospital fatalities will all have the value 0, while everybody else will have
outcomes ranging from 0 to 90. Such outcomes are also routinely analyzed using Wilcox-type test.
Our proposed test would increase power while also providing a mean effect estimate along with
confidence bands. Note also that the developed mathematical method allows straightforwardly
for the inclusion of confounders variables. The method itself is therefore just as applicable in
non-randomized studies or epidemiological studies in general.
The rest of the paper is structured as follows. The next section introduces the mathematical setup as
well as our novel test procedure. Section 3 describes the R implementation and Section 4 presents a
simulation study illustrating the substantial power gains. Finally, Section 5 discusses. Mathematical
proofs are contained in the appendix.
2 Method
We consider random variables (Y,A,R,X) where Y is the continuous outcome variable, A is a
binary variable being equal to 1 if Y is observed and equal to 0 if Y is unobserved/undefined, R is
a binary treatment indicator, and X is a p-dimensional vector of baseline covariates. The statistical
objective is to describe the distribution of ((Y | A = 1), A) | R,X where the primary hypothesis of
no treatment effect is given by ((Y | A = 1), A) ⊥ R | X.
Even though the outcome is bi-variate, a combined outcome is often used in practice. The combined
outcome is derived such that it is equal to Y if Y is observed, and otherwise it is equal to some
predetermined value. We can write this combined outcome as
Y˜ = Y 1A=1 + E1A=0 (1)
where E is a fixed atom assigned as the outcome value when Y is unobserved. The semi-continuous
distribution of Y˜ is therefore a probabilistic mixture of a singular distribution at E and a continuous
2
distribution over the domain of the random variable Y | A = 1. Thus the statistical challenge be be
rephrased as assessing if the treatment (R) affects the distribution of Y˜ .
The conditional expected value of the combined outcome in Equation (1) is given by
E[Y˜ | R,X] = E[Y | R,X,A = 1]P (A = 1 | R,X) + EP (A = 0 | R,X)
From this expression one can show that a treatment comparison expressed in terms of a contrast
of the expectation of Y˜ can be zero even though the distribution of ((Y | A = 1), A) depends on
R. To see this, let E[Y | A = 1, R = 0, X] = µ(X) and E[Y | A = 1, R = 1, X] = µ(X) + µδ(X)
and assume without loss of generalization that E = 0. Then the average treatment effect for the
combined outcome conditional on baseline covariates is
∆(X) = E[Y˜ | R = 1, X]− E[Y˜ | R = 0, X] (2)
= µ(X) [P (A = 1 | R = 1, X)− P (A = 1 | R = 0, X)] + µδ(X)P (A = 1 | R = 1, X)
If we auspiciously let µδ(X) = µ(X)
[
P (A = 1 | R = 0, X)P (A = 1 | R = 1, X)−1 − 1] then ∆(X) =
0 for all values of X even though µδ(X) 6= 0 and P (A = 1 | R = 0, X) 6= P (A = 1 | R = 1, X).
On the other hand, if µδ(X) = 0 and P (A = 1 | R = 1, X) = P (A = 1 | R = 0, X) then ∆(X) is
necessarily equal to zero. This illustrates that a significance test of no treatment effect must have
two degrees of freedom. Such a test which we develop in the subsequent sections is conceptually
difference than a test for the null-hypothesis ∆(X) = 0. Noe that in RCTs one would typically not
include any variables X since these are balanced by design.
2.1 Likelihood ratio test
We propose to test the null-hypothesis of no treatment effect on the combined outcome by a
likelihood ratio test of the joint distribution of Yi | Ai and Ai. This has the advantage that it
increases the efficiency compared the Wilcoxon test and it yields a single p-value appropriate for
testing a primary outcome in a clinical trial. Let (Yi, Ai, Ri, Xi) for i = 1, . . . , n be independent and
identically distributed random variables. We can write our model in a general form as
Yi | Ai = 1, Ri, Xi ∼ F (Yi;µi(Ri, Xi),Ψ)
Ai | Ri, Xi ∼ Bernoulli(Ai;pii(Ri, Xi))
for some mean functions pii and µi and a distribution function F characterizing the distribution of
the observed continuous outcomes with possible nuisance parameter Ψ. The joint likelihood function
for the combined outcome conditional on treatment and baseline covariates is
Ln(µi(Ri, Xi), pii(Ri, Xi),Ψ) =
n∏
i=1
f(Yi;µi(Ri, Xi),Ψ)AiP (Ai = ai;pii(Ri, Xi))
=
n∏
i=1
f(Yi;µi(Ri, Xi),Ψ)Aipii(Ri, Xi)Ai(1− pii(Ri, Xi))1−Ai
3
We note that when F admits an absolutely continuous density function the likelihood function
can equivalently be written solely in terms of the combined outcome Y˜ in Equation (1) since
f(Yi; ·)Ai = f(Y˜i; ·)1Y˜i 6=E and pii(·)Ai = pii(·)1Y˜i 6=E almost surely. An important property of this model
is that the likelihood function factorizes into two components as
Ln(µi(Ri, Xi), pii(Ri, Xi)) = L1,n(µi(Ri, Xi),Ψ)L2,n(pii(Ri, Xi)) (3)
where L1,n(µi(Ri, Xi),Ψ) =
∏n
i=1 f(Yi;µi(Ri, Xi),Ψ)Ai and L2,n(pii(Ri, Xi)) =
∏n
i=1 pii(Ri, Xi)Ai(1−
pii(Ri, Xi))1−Ai . This implies that the parameters for the observed outcomes, µi(Ri, Xi), can be
estimated independently of the parameters governing the probability of observing the outcome,
pii(Ri, Xi). This factorization is a consequence of the likelihood construction and it does neither
assume nor require independence between the value of the outcome and the probability of observing
it.
Under the assumption of generalized linear models for µi(Ri, Xi) and pii(Ri, Xi) with additive
structures we may parametrize the mean functions as
E[Yi | Ai = 1, Ri, Xi] = µ0 + µδRi + sµ(Xi) (4)
logitP (Ai = 1 | Ri, Xi) = β0 + βδRi + sβ(Xi) (5)
where the treatment effect is quantified by bi-variate contrast (µδ, βδ) and sµ, sβ : Rp 7→ R are some
models for the baseline covariates. The parameter µδ is interpreted as the expected difference among
the observed outcomes and βδ is correspondingly the log odds-ratio of being observed.
To assess the effect of treatment on the combined outcome we propose a test statistic based on the
likelihood ratio statistic
Wn(µ0, µδ, sµ, β0, βδ, sβ) = −2 log
sup
Ψ
L1,n(µ0, µδ, sµ,Ψ)L2,n(β0, βδ, sβ)
sup
µ0,µδ,sµ,Ψ
L1,n(µ0, µδ, sµ,Ψ) sup
β0,βδ,sβ
L2,n(β0, βδ, sβ)
(6)
= W1,n(µ0, µδ, sµ)W2,n(β0, βδ, sβ) (7)
WPn (µδ, βδ) = sup
µ0,sµ
Wn,1(µ0, µδ, sµ) sup
β0,βs
Wn.2(β0, βδ, sβ) (8)
use the profile likelihood ratio test (LRT) statistic which can be written as a function of the
treatment effects as and the value of the LRT statistic under the null-hypothesis of no treatment
effect is therefore Wn(0, 0). Similar to the factorization of the likelihood function in Equation (3),
the LRT statistic in Equation (6) also decomposes into the sum
Wn(µδ, βδ) = W1,n(µδ) +W2,n(βδ) (9)
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of two LRT statistics – one for the continuous part and one for the discrete part of the combined
outcome. Under very general conditions it follows that Wn(µδ, βδ) is approximately χ2 distributed
with two degrees of freedom (Wilks 1938; A. B. Owen 1988).
In order to actually perform the test we still need to decide on an stochastic model for the continuous
part of the combined outcome, Yi | Ai = 1. In the following two sections we present both a parametric
approach based on a normal model and a flexible semi-parametric approach that does not require
distributional assumptions.
2.2 Parametric approach
If we combine the model for the expected value in Equation (4) with the assumption of normal
distributed outcomes of the continuous part of the combined outcome we obtain the following
sub-model
Yi | Ai = 1, Ri ∼ N
(
µ0 + µδRi, σ2
)
With the generalized linear models in Equations (4) and (5) the first term is the LRT statistic with a
single degree of freedom in a linear regression model, and the second term is the LRT statistic with
a single degree of freedom in a logistic regression model. This makes this test very easy to perform
in standard statistical software that outputs the likelihood value for a model fit without the need of
special methods. The calculation of the LRT simply amounts to estimating two linear regression
models and two logistic regression models – for each type a model with and a model without the
binary treatment indicator as a covariate. Combining the two likelihood ratios according to Equation
(9) calculates our test statistic, and the p-value for no treatment effect can be determined through
the χ2-distribution with two degrees of freedom. The critical value for rejecting the null-hypothesis
of no treatment effect at the 5% level is equal to 5.99 and equal to 9.21 at the 1% level.
A direct consequence of Wilks’ theorem (Wilks 1938) is given in the following proposition. Note
that the stated conditions are trivially satisfied for an RCT with fixed randomization proportions.
Proposition 1. Assume that P (Ai = 1 | Ri = r) > 0 for r = 0, 1 and let mj = ∑ni=1 1Ri=j.
Then the parametric profile likelihood ratio test statistic WPn (0, 0) stated in Equation (8) for the
null-hypothesis of no treatment effect on the combined outcome is asymptotically χ2 distributed with
two degrees of freedom for m1,m2 →∞ and m1/m2 → c for some finite, positive constant c.
2.3 Semi-parametric approach
A drawback of the parametric LRT introduced in the previous section is that it requires deciding on
a parametric distribution for the observed outcomes. In this section we introduce a more flexible
approach based on an empirical LRT. This approach also utilizes the additive decomposition of
the LRT statistic in Equation (9) but substitutes the term W1,n with a term that is free of any
distributional assumptions. Combining this with the binomial model for A leads to a semi-empirical
LRT for the treatment effect.
Let I0 = {i = 1, . . . , n : Ri = 0, Ai = 1} and I1 = {i = 1, . . . , n : Ri = 1, Ai = 1} be the sets of
indices of the observed outcomes for the two treatments. The empirical LRT statistic as a function
of the difference in expected value is given by
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WE1,n(µ∗δ) = 2 sup
µ
∑
i∈I0
log (1 + λ1(Yi − µ)) +
∑
j∈I1
log (1 + λ2(Yj − µ− µ∗δ))

where λ1 and λ2 are the solutions to the following equations
|I0|−1
∑
i∈I0
Yi − µ
1 + λ1(Yi − µ) = 0, |I1|
−1 ∑
j∈I1
Yj − µ− µ∗δ
1 + λ2(Yj − µ− β∗δ )
= 0
We refer to the appendix for a derivation of the test statistics.
The semi-parametric LRT statistic for testing the null-hypothesis of no treatment effect is equal to
WSPn (0, 0) where
WSPn (µ∗δ , α∗δ) = WE1,n(µ∗δ) +W2,n(α∗δ) (10)
By the non-parametric Wilk’s theorem (A. B. Owen 1988) it follows that WSPn (0, 0) ∼ χ22 asymptot-
ically.
Proposition 2. Assume that P (Ai = 1 | Ri = r) > 0 for r = 0, 1 and let mj = ∑ni=1 1Ri=j. Then
the semi-parametric profile likelihood ratio test statistic WSPn (0, 0) stated in Equation (10) for the
null-hypothesis of no treatment effect on the combined outcome is asymptotically χ2 distributed with
two degrees of freedom for m1,m2 →∞ and m1/m2 → c for some finite, positive constant c.
2.4 Confidence intervals
Confidence intervals for the treatment effects are readily available by inverting the LRT in Equation
(9) utilizing the duality between hypothesis testing and confidence intervals. Specifically, an
(1 − α)100% confidence region or interval contains all parameter values that cannot be rejected
according to the LRT at level α. The bi-variate confidence region for the treatment effect is therefore
given by the following point set in R2
CI(µδ,βδ)1−α =
{
(m, b) : W1,n(m) +W2,n(b) ≤ χ22(1− α)
}
and it will asymptotically contain the true difference in means among the observed outcomes and
the true log odds-ratio of being observed simultaneously with probability (1− α)100%. Similarly,
uni-variate confidence intervals for µδ and βδ can be computed by inversion with respect to a χ2
distribution with one degree of freedom, e.g.,
CIµδ1−α =
{
m : W1,n(m) ≤ χ21(1− α)
}
, CIβδ1−α =
{
b : W2,n(b) ≤ χ21(1− α)
}
The exact formula for the confidence interval for the average difference in the combined outcome (Y˜ )
depends on the chosen model for the binary component (A). However, it can always be calculated
using the Delta-method.
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3 R package
To facilitate a straightforward application of our approach we have implemented both the parametric
and semi-parametric likelihood ration tests in the R package TruncComp which is available at the
first author’s GitHub repository (Jensen and Lange 2018). We illustrate its applicability based on
an example data set also available from the package.
The example data set can be loaded by writing data("TruncCompExample") after loading the
package. The data set contains two variables, Y and R, where Y is the continuous outcome and R
is the binary treatment indicator. There are 25 observations in each treatment group, and truncated
observations in Y have been assigned the atom E = 0. Figure 1 shows histograms of the outcome
for each treatment group. Visually there appears to be a difference between the two groups both in
terms of the frequency of the atom and a location shift in the continuous part.
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Figure 1: Histograms of the outcome for the example data stratified by treatment group.
The observed difference in means for the combined outcome, ∆ in Equation (2), is 0.018 and both a
two-sample t-test and a Wilcoxon rank sum test show highly insignificant effects of the treatment
with p-values of 0.984 and 0.696 respectively. In order to analyse the data using proposed method
we use the function truncComp as follows
model <- truncComp(Y ~ R, atom = 0, data = TruncCompExample, method="SPLRT")
where the formula interface is similar to other regression models implemented in R. The argument
atom identifies the value assigned to the unobserved outcomes, and method can be SPLRT or LRT for
either the semi-parametric or the parametric likelihood ratio test, respectively. In this example we
have opted for the semi-parametric version to show how easily this additional flexibility is included.
We obtain the results of the estimation by a calling the function summary on the estimated model:
summary(model)
## Estimation method: Semi-empirical Likelihood Ratio Test
## Confidence level = 95%
##
## Treatment contrasts
7
## Estimate CI Lower CI Upper
## Difference in means among the observed: 1.8564296 1.1638863 2.480132
## Odds ratio of being observed: 0.5238095 0.1660407 1.596820
##
## Joint test statistic: W = 31.09545
## p-value: p = 1.768924e-07
The output from the call to summary displays estimates for the two treatment contrasts corresponding
to µδ and eαδ in Equations (4) and (5). These contrasts quantify the difference in means among the
observed outcomes and the odds ratio of being observed respectively in accordance with the model
specification. Each estimated treatment contrast is accompanied with a confidence interval, and
finally the output displays the joint likelihood ratio test statistic and the associated p-value for the
joint null-hypothesis of no treatment effect.
From the output we see that the semi-parametric likelihood ratio analysis reports an extremely low
p-value for null-hypothesis of no joint treatment effect. This strongly contradicts the conclusions
from both the previous t- and Wilcoxon analyses. The confidence intervals for the two treatment
contrasts indicate that the average value for the observed outcome in the group defined by R = 1 is
significantly higher than the average value for the observed outcome in the group with R = 0.
The confidence intervals can also be obtained by calling the function confint on the model object.
This command reports both the marginal confidence intervals for the two treatment contrasts as
well as a their simultaneous confidence region. To obtain the simultaneous confidence region we
write
confint(model, type="simultaneous", plot=TRUE, resolution = 50)
where resolution is the number of grid points on which the surface is evaluated. Figure 2 shows a
heat-map of the semi-empirical likelihood surface as well as the 95% confidence region. The point
(0, 0) is far outside of the joint confidence region which corresponds to the strong rejection of the
joint null hypothesis of nu treatment effect.
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Figure 2: Simultaneous empirical likelihood ratio surface for the two treatment contrasts.
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4 Simulation study
To illustrate the power benefit and small sample properties of our proposed procedure we consider 4
setups, which we examine by simulations. In all simulations setups it is assumed that treatment is
randomized 1:1. We will vary both the mean among survivors (denoted µ0 and µ1) and probability
of death (p0 and p1). For the first three simulation setup values among survivors are assumed to
follow a normal distribution with unit variance and the stated means. We will also consider the
effect of heavily right skewed data among the survivors (simulation setup 4, which uses the square
of a t-distribution with 2 degrees of freedom multiplicatively scaled to having the right mean. Table
1 below presents the considered simulation setups. It is noted that in simulation setups 3 and 4 the
effect on the survivors and the effect on mortality are in opposite directions.
Table 1: Simulation setups. ∆ denotes the marginal mean when setting the outcome to zero for
the dead.
µ0 µ1 pi0 pi1 Distribution ∆
Setup 1 3.0 4.0 0.35 0.35 Normal (sd=1) -0.3476400
Setup 2 3.5 3.5 0.40 0.30 Normal (sd=1) 0.3481800
Setup 3 3.0 4.0 0.40 0.30 Normal (sd=1) 0.0035646
Setup 4 3.0 4.0 0.40 0.30 t-dist (df=2) squared -1.0058211
To assess power we vary the sample size from 25 to 250 and for each configuration we conduct
100,000 Monte Carlo replications and compute power. The resulting power curves are presented in
Figure 3. In setup 1 we observe a large power gain compared to the Wilcox test. Here the Wilcox
tests gets “confused” by the large number of ties in the atom. In setup 2 Wilcox test has slightly
better power profile. This is to be expected as our novel test is here disadvantaged by being a
two-degrees-of-freedom test where the Wilcox is only one. It is further observed that Wilcox as
expected as very little power when the effects on mortality and among survivors are of opposite sign
despite the two distributions being markedly different indicating clear treatment effect (setups 3 and
4). In contrast our novel methods has excellent power. In all settings with a normally distributed
outcome among survivors the parametric and semi-parametric approaches are similar, but for the
heavy tail setup (no. 4) the semi-parametric approach is clearly superior.
5 Discussion
In this paper we introduce a novel statistical test to assess treatment effect on continuous outcomes
where one value has special meaning (e.g., all diseased are assigned lowest possible value). The
procedure in potentially much more power-full than the current best-practice which is to use Wilcox-
type tests. The proposed method includes both a fully parametric approach and a semi-parametric
where one makes no assumptions on the functional form of the continuous part of the distribution.
In all settings the new method not only provide an effect measure but also effect parameters with
associated confidence intervals. The test is implemented in an R package available on GitHub.
It is noted that unlike the Wilcox test out proposed method can easily be extended to include
covariates (A. Owen 1991). It is therefor not only useful in an RCT setting but also to observed
data.
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Figure 3: Simulated power as a function of sample size for each of the four scenarios in Table 1.
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Appendix
Derivation of semi-parametric test quantity
The empirical likelihood ratio function that compares the empirical maximum likelihood under a
constraint set C to an unconstrained maximum likelihood is given by
RE1,n(C) =
sup
{pi}
(∏
i∈I0 pi | C
)
sup
{qj}
(∏
j∈I1 qj | C
)
sup
F∈F
∏
i∈I0 F ({Yi}) sup
G∈F
∏
j∈I1 G({Yj})
(11)
where F is the family of cadlag functions. This empirical likelihood ratio is simply a comparison
between the non-parametric unconstrained maximum likelihood values and a a null-model where
the maximum likelihoods in the two treatment groups are constrained according to a constraint
set C. The sets of weights, {pi} and {qj}, form a constrained multinomial distribution over the
observations.
It is well-known that the solutions to the two unconstrained maximizations in the denominator are
given by the empirical distribution functions that put equal weight on each observation. From here
it follows that the likelihood ratio function can be written as
RE1,n(C) = sup
{pi},{qj}
∏
i∈I0
|I0|pi
∏
j∈I1
|I1|qj | C
 (12)
where | · | denotes the cardinality of the index set.
The constraint set is chosen so that {pi} and {qj} are bona fide multinomial distributions, and so
that the expected value of the observations with indices in I0 have expectation β and the difference
between the expectations comparing the observations with indices in I1 to those with indices in I0
is given by βδ similar to the structure of the linear model in Equation (5). This yields the following
set of constraints:
pi ≥ 0,
∑
i∈I0
pi = 1,
∑
i∈I0
pi(Yi − β) = 0 (13)
qj ≥ 0,
∑
j∈I1
qj = 1,
∑
j∈I1
qj(Yj − β − βδ) = 0 (14)
The find the values of {pi} and {qj} in Equation (12) that satisfies the constraint set we solve the
constrained optimization problem through the following objective function
O({pi} , {qj}) =
∑
i∈I0
log(|I0|pi) +
∑
j∈I1
log(|I1|qj) + γ1
∑
i∈I0
pi − 1
+ γ2
∑
j∈I1
qj − 1
 (15)
− |I0|λ1
∑
i∈I0
pi(Yi − β)− |I1|λ2
∑
j∈I1
qj(Yj − β − βδ)
11
where γ1, γ2, λ1 and λ2 are Lagrange multipliers.
Calculating the partial derivatives of O({pi} , {qj}) with respect to pi and qi and setting them equal
to zero we have that
0 = ∂
∂pi
O({pi} , {qj}) = 1
pi
− |I0|λ1(Yi − β) + γ1 (16)
0 = ∂
∂qj
O({pi} , {qj}) = 1
qj
− |I1|λ2(Yj − β − βδ) + γ2 (17)
and by applying the constrains it follows that
0 =
∑
i∈I0
pi
∂O({pi} , {qj})
∂pi
(18)
=
∑
i∈I0
pi
( 1
pi
− |I0|λ1(Yi − µ) + γ1
)
=
∑
i∈I0
1− |I0|λ1
∑
i∈I0
pi(Yi − β) + γ1
∑
i∈I0
pi
= |I0|+ γ1
Therefore γ1 = −|I0| and γ2 = −|I1| by similar calculation for qj . From Equations (16) and (17)
and the previous results we obtain the following solutions
pi =
1
|I0|(1 + λ1(Yi − β)) , qj =
1
|I1|(1 + λ2(Yj − β − βδ)) (19)
and by inserting these expressions into the expression for the empirical likelihood ratio we obtain
logRE1,n(β, βδ) =
∑
i∈I0
log(|I0|pi) +
∑
j∈I1
log(|I1|qj) (20)
=
∑
i∈I0
log 11 + λ1(Yi − β) +
∑
j∈I1
log 11 + λ2(Yj − β − βδ)
= −
∑
i∈I0
log (1 + λ1(Yi − µ))−
∑
j∈I1
log (1 + λ2(Yj − β − βδ))
The values of λ1 and λ2 can then be found by combining Equations (16) and (17) with the constraints
leading to the following set of equations
|I0|−1
∑
i∈I0
Yi − β
1 + λ1(Yi − β) = 0, |I1|
−1 ∑
j∈I1
Yj − β − βδ
1 + λ2(Yj − β − βδ) = 0 (21)
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that in practice can be solved for λ1 and λ2 using a numerical root finding method.
The empirical LRT statistic is therefore
WE1,n(β, βδ) = −2 logRE1,n(β, βδ) (22)
= 2
∑
i∈I0
log (1 + λ1(Yi − β)) +
∑
j∈I1
log (1 + λ2(Yj − β − βδ))

where WE1,n(β∗δ ) = sup
β
WE1,n(β, β∗δ ) the profile version testing the difference between treatments.
13
